Publication:
Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries

dc.contributor.authorVarunika Ruwanpuraen_US
dc.contributor.authorJosselyn Neukomen_US
dc.contributor.authorKoen Peeters Grietensen_US
dc.contributor.authorRic N. Priceen_US
dc.contributor.authorKamala Thriemeren_US
dc.contributor.authorCaroline A. Lynchen_US
dc.contributor.otherFaculty of Tropical Medicine, Mahidol Universityen_US
dc.contributor.otherPrins Leopold Instituut voor Tropische Geneeskundeen_US
dc.contributor.otherMenzies School of Health Researchen_US
dc.contributor.otherNagasaki Universityen_US
dc.contributor.otherNuffield Department of Medicineen_US
dc.contributor.otherMedicines for Malaria Ventureen_US
dc.contributor.otherIndependent Consultanten_US
dc.date.accessioned2022-08-04T08:45:42Z
dc.date.available2022-08-04T08:45:42Z
dc.date.issued2021-12-01en_US
dc.description.abstractBackground: The changing global health landscape has highlighted the need for more proactive, efficient and transparent health policy-making. After more than 60 years of limited development, novel tools for vivax malaria are finally available, but need to be integrated into national policies. This paper maps the malaria policy-making processes in seven endemic countries, to identify areas where it can be improved to align with best practices and optimal efficiency. Methods: Data were collected during a workshop, convened by the Asia Pacific Malaria Elimination Network’s Vivax Working Group in 2019, and subsequent interviews with key stakeholders from Cambodia, Ethiopia, Indonesia, Pakistan, Papua New Guinea (PNG), Sri Lanka and Vietnam. Documentation of policy processes provided by respondents was reviewed. Data analysis was guided by an analytic framework focused on three a priori defined domains: “context,” “actors” and “processes”. Results: The context of policy-making varied with available funding for malaria, population size, socio-economic status, and governance systems. There was limited documentation of the process itself or terms of reference for involved actors. In all countries, the NMP plays a critical role in initiating and informing policy change, but the involvement of other actors varied considerably. Available evidence was described as a key influencer of policy change; however, the importance of local evidence and the World Health Organization’s endorsement of new treatments and diagnostics varied. The policy process itself and its complexity varied but was mostly semi-siloed from other disease specific policy processes in the wider Ministry of Health. Time taken to change and introduce a new policy guideline previously varied from 3 months to 3 years. Conclusions: In the medium to long term, a better alignment of anti-malarial policy-making processes with the overall health policy-making would strengthen health governance. In the immediate term, shortening the timelines for policy change will be pivotal to meet proposed malaria elimination milestones.en_US
dc.identifier.citationMalaria Journal. Vol.20, No.1 (2021)en_US
dc.identifier.doi10.1186/s12936-021-03959-wen_US
dc.identifier.issn14752875en_US
dc.identifier.other2-s2.0-85118336989en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/77141
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118336989&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleOpening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countriesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118336989&origin=inwarden_US

Files

Collections